More than half of prostate cancer patients undergo radiation treatment which may be accompanied by acute or late side effects in genitourinary, GU, and/or gastrointestinal, GI tract, and radiotherapy-induced fatigue (RIF).
The biological role of RNase L highlights its potential to be tested for association with the adverse effects of radiotherapy.
